Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827118 | 1.00 | KMT2A (0.65) | KMT2AMAPK1SMN1; SMN2KDM4EGAA | |
| SCHEMBL2037341 | 0.84 | LMNA (0.65) | KMT2AMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30379991 | 0.84 | KMT2A (0.61) | KMT2AMAPK1KDM4ERAB9AALDH1A1 | |
| SCHEMBL3864912 | 0.84 | KMT2A (0.61) | KMT2AMAPK1KDM4ERAB9AALDH1A1 | |
| SCHEMBL31602400 | 0.83 | KDM4E (0.67) | KMT2AMAPK1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL3597779 | 0.83 | KMT2A (0.59) | KMT2AMAPK1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL30229742 | 0.83 | KMT2A (0.59) | KMT2AMAPK1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL22610155 | 0.81 | CDK4 (0.60) | KMT2AMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9701534 | 0.81 | KMT2A (0.71) | KMT2AMAPK1NTSR1CDK4CCND1 | |
| SCHEMBL30074152 | 0.81 | KMT2A (0.71) | KMT2AMAPK1NTSR1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101157650-B | Method for preparation of indole-1-methyl formate and its derivatives | UNIV EAST CHINA NORMAL | 2011-04-27 | — | — | CN | claimed |
| US-9174980-B2 | Heterocyclic compounds as inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174980-B2 | Heterocyclic compounds as inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-1276721-B1 | METHYLATION OF INDOLE COMPOUNDS USING DIMETHYL CARBONATE | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013116182-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | WO | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| CN-101085778-B | Preparation method for etodolac | SHANDONG XINHUA PHARMACEUTICAL | 2010-05-19 | — | — | CN | disclosed |
| US-7566791-B2 | Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566791-B2 | Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2009-07-28 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0539117-B1 | Compounds useful as leukotriene antagonists | LILLY CO ELI (GB) | 1998-03-11 | — | — | EP | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| US-5410061-A | Leukotriene antagonist | LILLY INDUSTRIES LIMITED (GB) | 1995-04-25 | — | — | US | disclosed |
| EP-0539117-A1 | Compounds useful as leukotriene antagonists | LILLY INDUSTRIES LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
| US-5196541-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-AMINOACRYLIC ESTERS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5132319-A | Antiasthmatic, antiinflammatory, antiallergen and cytoprotective agents | MERCK FROSST CANADA, INC. (CA) | 1992-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | KMT2A 3584/4885MAPK1 2025/4885SMN1; SMN2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.